Revive Therapeutics high on IRB approval for Bucillamine Phase 3 clinical trial
Revive Therapeutics high on IRB approval for Bucillamine Phase 3 clinical trial
SeekingAlpha
0 shares
1 views
You might like
Related news coverage
NA Proactive news snapshot: Aequus Pharmaceuticals, Acasti Pharma, Internet of Things, Revive Therapeutics UPDATE ....
Proactive Investors
Aequus Pharmaceuticals Inc (CVE:AQS) (OTCQB:AQSZF) is getting ready to file for regulatory approval in Canada for the Evolve line..
-
Revive Therapeutics wins Institutional Review Board approval for its Phase 3 trial protocol to evaluate Bucillamine in COVID-19 patients
Proactive Investors
-
NA Proactive news snapshot: Cardiol Therapeutics, Gold Resource Corporation, HighGold Mining, Revive Therapeutics, Newgioco Group, KULR Technology UPDATE …
Proactive Investors
-
NA Proactive news snapshot: Revive Therapeutics, Newgioco Group, KULR Technology, Phunware, Killi UPDATE …
Proactive Investors
-
Revive Therapeutics submits Phase 3 trial protocol of possible COVID-19 drug Bucillamine to the Institutional Review Board
Proactive Investors
Advertisement
More coverage
Antibe Therapeutics plans to file IND with regulator for lead drug otenaproxesul
Proactive Investors
Antibe Therapeutics Inc (CVE:ATE) (OTCQB:ATBPF) has revealed that it plans to file an Investigational New Drug (IND) application..
-
Kazia Therapeutics soars on award of US FDA Fast Track Designation to paxalisib for glioblastoma
Proactive Investors
-
NA Proactive news snapshot: Cardiol Therapeutics, Revive Therapeutics, Ximen Mining, Canada Silver Cobalt Works, BioPorto, PUDO UPDATE …
Proactive Investors
-
Revive Therapeutics Ltd broadens Phase 3 coronavirus trial of Bucillamine to Asia-Pacific and Canada
Proactive Investors
-
NA Proactive news snapshot: BioPorto, PUDO, CleanSpark, Falcon Gold, MGX Minerals UPDATE …
Proactive Investors